Effect of vitamins, minerals, and trace elements on human health with a focus on the urogenital system. What are the risks involved in their deficiency or overdose? – 1st part

Jiří Kladenský

Prakt. Lékáren. 2017; 13(3e)  

Abundant literature has been published on the effect of vitamins on the human body. Given the fact that some of the publications are produced by the manufacturers of food supplements themselves, these are frequently written in a tendentious way in order to persuadethe reader of the necessity of taking such products, and their scientific validity is often biased. If we wanted to address the effect of vitaminsin detail, even the entire issue of this journal would not suffice. Therefore, the review article presents, in a relatively brief manner, thefundamental facts for you, doctors-urologists, as a kind of reminder; and since a number of these substances...

Effect of vitamins, minerals, and trace elements on human health with a focus on the urogenital system. What are the risks involved in their deficiency or overdose? – 2nd part

Jiří Kladenský

Prakt. Lékáren. 2017; 13(3e)  

What was mentioned in the previous chapter on the effect of vitamins on the human body applies as well to minerals and trace elements, namely thatabundant literature has been published on their effect on the human body; however, given the fact that some of the publications are produced bythe manufacturers of food supplements themselves, these are frequently written in a tendentious way in order to persuade the reader of the necessityof taking such products, and their scientific validity is often biased. For this reason, there is a risk that, due to excessive use because of advertising, theusers of these food supplements can relatively easily overdose...

Some comments on the 2016 ESC/EAS guidelines for diagnosing and treating dyslipidaemias

Michal Vrablík

Prakt. Lékáren. 2017; 13(3e)  

The ESC/EAS guidelines for the management of dyslipidaemias published in August 2016 represent a large reference document summarizingthe development over the five years since the first version was published in 2011. They reflect the knowledge achieved in many areas – fromdiagnosis and cardiovascular risk stratification to setting therapeutic goals and guiding management to the issue of dyslipidaemias in selectedspecific groups of patients. Also discussed are medication adverse effects or the current issue of adherence. The present article highlightsselected sections from the comprehensive document by briefly commenting on them.

Monoclonal antibodies in treating high cholesterol levels

Rostislav Večeřa

Prakt. Lékáren. 2017; 13(3e)  

Proprotein convertase subtilisin-kexin type 9 (PCSK9) is mainly responsible for the recycling receptors for LDL particles. This results in an increasein LDL levels, which then drastically contributes to the development of atherosclerotic changes in vessel wall. This increases cardiovascularmorbidity and mortality. New drugs based on monoclonal antibodies as alirocumab or evolocumab belongs among PCSK9 inhibitors. Theiradministration leads to a dramatic reduction in LDL particles up to 50–60 %. Given that the Czech Republic ranks among the countries withhigh cardiovascular mortality, is introduction of these new drugs in clinical practice one...

Evaluation of inquiries on drug-drug interactions in internet advisory center „I know my medicaments“

Michal Prokeš, Petr Průša, Josef Suchopár, Ondřej Suchopár

Prakt. Lékáren. 2017; 13(3e)  

Drug interactions are one of the main risks of pharmacotherapy in all developed countries of the world. Patients using multiple medicationsare sometimes concerned with the safety of drug-drug combinations they use. Advisory web center „I know my medicaments“ was establishedby AIFP to give patients basic information, whether drug-drug combinations they use are fundamentally safe or whether some risk is present. The drug lists issued by patiens to advisory center was evaluated by experts with the aid of electronic DrugAgency a. s. database of drug-druginteractions. Answers were sent back to patiens, and the drug-drug interactions, as well...

System of continuing education of pharmacists in Great Britain

Michal Papáček, Alena Petříková

Prakt. Lékáren. 2017; 13(3e): e50-e54  

This article focuses on system of continuous education of British pharmacists. This system is compulsory and is regulated by the General PharmaceuticalCouncil and its Professional Standard. It is based on the concept of Continuing Professional Development (CPD). Pharmacists areencouraged to undertake CPD in any area that leads to increasing quality of care and improved patient safety safety in their individual pharmacypractice. The „CPD cycle“ model is the fundamental tool for CPD participation and its recording. CPD can have any form, most commonforms include attending training events, self-directed learning, e-learning and reflection...

E-verze 3/17

Prakt. Lékáren. 2017; 13(3e)